Erasca (ERAS) Share-based Compensation (2020 - 2026)
Erasca (ERAS) reported Share-based Compensation of $8.5 million for Q1 2026, up 26.02% on a YoY basis from $6.7 million in Q1 2025, and up 45.29% quarter-over-quarter from $5.8 million in Q4 2025.
Erasca (ERAS) Share-based Compensation (2020 - 2026) Analysis & Trends
Erasca has reported Share-based Compensation for 7 years, with the latest figure at $8.5 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 26.02% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $26.6 million (down 0.72% YoY), and the FY2025 full-year result was $24.9 million, down 7.69% from the prior year.
- Share-based Compensation for Q1 2026 stood at $8.5 million, up from $5.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $8.5 million in Q1 2026, with the low at $4.4 million in Q1 2022.
- Historically, Share-based Compensation has averaged $6.3 million across 5 years, with a median of $6.3 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 458.74% — and 2025, when it slipped 10.89%.
- Erasca's Share-based Compensation stood at $5.4 million in 2022, then increased by 14.05% to $6.1 million in 2023, then increased by 2.8% to $6.3 million in 2024, then declined by 7.69% to $5.8 million in 2025, then surged by 45.29% to $8.5 million in 2026.
- The last three Share-based Compensation figures came in at $8.5 million (Q1 2026), $5.8 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 8.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.46 Mn |
| Mar 31, 2026 | 8.46 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Sep 30, 2025 | 5.97 Mn |
| Sep 30, 2025 | 5.97 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Dec 31, 2023 | 6.14 Mn |
| Dec 31, 2023 | 6.14 Mn |